Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Pharmacologic Substance
>
MRNA Vaccines
MRNA Vaccines
mRNA Vaccines are a novel class of vaccines that utilize messenger ribonucleic acid (mRNA) to instruct the body's cells to produce specific proteins, triggering an immune response.
This emerging technology holds great promise for the development of safe, effective, and rapidly deployable vaccines against a variety of infectious diseases, including COVID-19. mRNA Vaccines offer several advantages over traditional vaccine approaches, such as the ability to induce a strong immune response, the potential for rapid manufacturing, and the potential for improved stability and storage conditions.
Reserarch in this field is rapidly evolving, with ongoing efforts to optimize mRNA vaccine design, delivery, and production methods to enhance potnecy, safety, and scalability.
Leveraging the power of AI-driven analysis can help accelerate the development of mRNA Vaccines and bring this transformative technology to the forefront of modern vaccinology.
This emerging technology holds great promise for the development of safe, effective, and rapidly deployable vaccines against a variety of infectious diseases, including COVID-19. mRNA Vaccines offer several advantages over traditional vaccine approaches, such as the ability to induce a strong immune response, the potential for rapid manufacturing, and the potential for improved stability and storage conditions.
Reserarch in this field is rapidly evolving, with ongoing efforts to optimize mRNA vaccine design, delivery, and production methods to enhance potnecy, safety, and scalability.
Leveraging the power of AI-driven analysis can help accelerate the development of mRNA Vaccines and bring this transformative technology to the forefront of modern vaccinology.
Most cited protocols related to «MRNA Vaccines»
1-methylpseudouridine
3' Untranslated Regions
Asian Americans
bacteriophage T7 RNA polymerase
Buffers
Cholesterol
Dialysis
Endotoxins
Ethanol
Exons
Genes
Homo sapiens
Influenza
Lipids
Molar
Nitrogen
Poly(A) Tail
RNA, Messenger
Signal Peptides
Sodium Acetate
Sodium Citrate
Strains
Sucrose
Transcription, Genetic
Tromethamine
Uridine
Zika Virus
To estimate the effectiveness of booster vaccination with either the BNT162b2 or mRNA-1273 vaccines, as compared with that of the two-dose primary series, we used a matched retrospective cohort study design that emulated a target trial.21 (link),22 (link) The study compared the incidence of symptomatic breakthrough SARS-CoV-2 infection among persons who had received the booster dose more than 7 days previously (the booster cohort) with the incidence among persons who had not yet received a booster dose (the nonbooster cohort). The 7-day cutoff between the administration of the booster and the start of follow-up was informed by earlier studies22-24 (link) to ensure sufficient time for the buildup of immune protection. A 14-day cutoff was also investigated in a sensitivity analysis.
All persons who had received at least two doses of the BNT162b2 vaccine between January 5, 2021 (the date of the first two-dose BNT162b2 vaccination series in Qatar), and January 26, 2022 (the end of the study), could be included in the eligible cohorts of the study, provided that they had no previous documented infection before the start of follow-up. The same inclusion criteria applied to persons who had received the mRNA-1273 vaccine, but the corresponding dates were January 24, 2021, and January 26, 2022, respectively.
Matching was used to identify a cohort of patients with similar baseline characteristics. Persons in the booster cohort and those in the nonbooster cohort were matched exactly in a 1:1 ratio according to sex, 10-year age group, and nationality to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.15 (link),25-28 (link) In a previous study that had a similar design, matching according to these factors was shown to provide adequate control of bias arising from differences in this risk. In that study, no meaningful difference between the matched mRNA-1273–vaccinated and BNT162b2-vaccinated cohorts was noted in the incidence of infection in the first 2 weeks after administration of the first dose,11 (link) as had been expected, given the negligible vaccine protection in this 2-week period.8 (link),9 (link) Moreover, in previous studies using other designs but the same matching, no meaningful difference was observed between vaccinated persons and unvaccinated persons with respect to the incidence of infection in the first 2 weeks after administration of the first dose.1 (link),2 (link),20 (link),29 (link)In our study, persons were also matched exactly according to the calendar week of the second-dose vaccination in order to control for the time since vaccination and the waning of vaccine immunity over time.1 (link),2 (link),10 (link),11 (link) Matching was performed through an iterative process that ensured that each control person in the nonbooster cohort was alive, infection-free, and had not received the third dose of vaccine by the beginning of follow-up. For each matched pair, follow-up began on the eighth day after the person in the booster cohort received the booster dose, provided this day occurred during the wave of infections with the omicron variant (e.g., on or after December 19, 2021). The large exponential-growth phase of this wave of infections started on December 19, 2021, and reached its peak in mid-January 2022.7 (link),30 Viral whole-genome sequencing of 315 random SARS-CoV-2–positive specimens collected between December 19, 2021, and January 22, 2022, was performed on a GridION sequencing device (Oxford Nanopore Technologies). Of these specimens, 300 (95.2%) were confirmed to be omicron infections and 15 (4.8%) were confirmed to be delta (or B.1.617.2)5 infections.7 (link),30 No cases of infection with the delta variant were detected in the viral whole-genome sequencing after January 8, 2022.
Persons in the booster cohort who had received the booster dose at least 7 days before the onset of the wave of omicron infections were followed along with their matched controls in the nonbooster cohort beginning on December 19, 2021. Controls in the nonbooster cohort who received the booster dose at a future date were eligible for recruitment into the booster cohort, provided they were alive and infection-free at the start of follow-up. Accordingly, some persons contributed follow-up time both as persons who had received only a two-dose primary series and as persons who had received a booster, but at different times.
To ensure exchangeability, data on both members of each matched pair were censored once the control received the booster dose.22 (link) Accordingly, follow-up continued until the first of one of these events: a documented SARS-CoV-2 infection (defined as the first positive PCR or rapid antigen test after the start of follow-up, regardless of the presence of symptoms or the reason for testing [this information was available only for PCR tests]), booster vaccination of the control (with matched pair censoring), death, or the end of study censoring (on January 26, 2022).
All persons who had received at least two doses of the BNT162b2 vaccine between January 5, 2021 (the date of the first two-dose BNT162b2 vaccination series in Qatar), and January 26, 2022 (the end of the study), could be included in the eligible cohorts of the study, provided that they had no previous documented infection before the start of follow-up. The same inclusion criteria applied to persons who had received the mRNA-1273 vaccine, but the corresponding dates were January 24, 2021, and January 26, 2022, respectively.
Matching was used to identify a cohort of patients with similar baseline characteristics. Persons in the booster cohort and those in the nonbooster cohort were matched exactly in a 1:1 ratio according to sex, 10-year age group, and nationality to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.15 (link),25-28 (link) In a previous study that had a similar design, matching according to these factors was shown to provide adequate control of bias arising from differences in this risk. In that study, no meaningful difference between the matched mRNA-1273–vaccinated and BNT162b2-vaccinated cohorts was noted in the incidence of infection in the first 2 weeks after administration of the first dose,11 (link) as had been expected, given the negligible vaccine protection in this 2-week period.8 (link),9 (link) Moreover, in previous studies using other designs but the same matching, no meaningful difference was observed between vaccinated persons and unvaccinated persons with respect to the incidence of infection in the first 2 weeks after administration of the first dose.1 (link),2 (link),20 (link),29 (link)In our study, persons were also matched exactly according to the calendar week of the second-dose vaccination in order to control for the time since vaccination and the waning of vaccine immunity over time.1 (link),2 (link),10 (link),11 (link) Matching was performed through an iterative process that ensured that each control person in the nonbooster cohort was alive, infection-free, and had not received the third dose of vaccine by the beginning of follow-up. For each matched pair, follow-up began on the eighth day after the person in the booster cohort received the booster dose, provided this day occurred during the wave of infections with the omicron variant (e.g., on or after December 19, 2021). The large exponential-growth phase of this wave of infections started on December 19, 2021, and reached its peak in mid-January 2022.7 (link),30 Viral whole-genome sequencing of 315 random SARS-CoV-2–positive specimens collected between December 19, 2021, and January 22, 2022, was performed on a GridION sequencing device (Oxford Nanopore Technologies). Of these specimens, 300 (95.2%) were confirmed to be omicron infections and 15 (4.8%) were confirmed to be delta (or B.1.617.2)5 infections.7 (link),30 No cases of infection with the delta variant were detected in the viral whole-genome sequencing after January 8, 2022.
Persons in the booster cohort who had received the booster dose at least 7 days before the onset of the wave of omicron infections were followed along with their matched controls in the nonbooster cohort beginning on December 19, 2021. Controls in the nonbooster cohort who received the booster dose at a future date were eligible for recruitment into the booster cohort, provided they were alive and infection-free at the start of follow-up. Accordingly, some persons contributed follow-up time both as persons who had received only a two-dose primary series and as persons who had received a booster, but at different times.
To ensure exchangeability, data on both members of each matched pair were censored once the control received the booster dose.22 (link) Accordingly, follow-up continued until the first of one of these events: a documented SARS-CoV-2 infection (defined as the first positive PCR or rapid antigen test after the start of follow-up, regardless of the presence of symptoms or the reason for testing [this information was available only for PCR tests]), booster vaccination of the control (with matched pair censoring), death, or the end of study censoring (on January 26, 2022).
2019-nCoV Vaccine mRNA-1273
Age Groups
Antigens
BNT162B2
COVID 19
Hypersensitivity
Infection
Medical Devices
mRNA Vaccine
mRNA Vaccines
Patients
Response, Immune
SARS-CoV-2
Secondary Immunization
Vaccination
Vaccines
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
COVID-19 Vaccines
COVID 19
Ethics Committees
Ethics Committees, Research
Health Care Professionals
Health Personnel
Human Body
Pharmaceutical Preparations
Safety
Vaccination
The study assessed the effectiveness of previous infection, vaccination with BNT162b2 or mRNA-1273, and hybrid immunity (previous infection and vaccination) against symptomatic infection with BA.1, BA.2, and any omicron infection.2 (link),15-18 (link) We used a test-negative, case–control design, in which effectiveness estimates were derived by comparing the odds of previous infection or vaccination or both among case participants (persons with a positive PCR test) with that among controls (PCR-negative persons).2 (link),15-18 (link) We also assessed effectiveness against any severe, critical, or fatal case of Covid-19.
To estimate the effectiveness against symptomatic infection, we exactly matched cases and controls that were identified from December 23, 2021, through February 21, 2022. Case participants and controls were matched in a 1:1 ratio according to sex, 10-year age group, nationality, and calendar week of PCR test. Matching was performed to control for known differences in the risk of SARS-CoV-2 exposure in Qatar.10 (link),19 (link),20 (link) Matching according to these factors was previously shown to provide adequate control of differences in the risk of SARS-CoV-2 exposure in studies of different designs, all of which involved control groups, such as test-negative, case–control studies.11 (link),12 (link),15 (link),21 (link),22 (link) To assess effectiveness against any severe, critical, or fatal case of Covid-19, we used a 1:5 matching ratio to improve the statistical precision of the estimates.
Only the first PCR-positive test that was identified for an individual participant during the study period was included, but all PCR-negative tests were included. Controls included persons with no record of a PCR-positive test during the study period. Only PCR tests conducted because of clinical symptoms were used in the analyses.
SARS-CoV-2 reinfection is conventionally defined as a documented infection that occurs at least 90 days after an earlier infection, to avoid misclassification of prolonged PCR positivity as reinfection if a shorter time interval is used.2 (link),23 (link) Previous infection was therefore defined as a PCR-positive test that occurred at least 90 days before the PCR test used in the study. Tests for persons who had PCR-positive tests that occurred within 90 days before the PCR test used in the study were excluded. Accordingly, previous infections in this study were considered to be due to variants other than omicron, since they occurred before the omicron wave in Qatar.2-4 (link)PCR tests for persons who received vaccines other than BNT162b2 or mRNA-1273 and tests for persons who received mixed vaccines were excluded from the analyses. Tests that occurred within 14 days after a second dose or 7 days after a third dose of vaccine were excluded. These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4 (link),14 (link) and to minimize different types of potential bias, as informed by earlier analyses in the same population.12 (link),22 (link) Every control that met the inclusion criteria and that could be matched to a case was included in the analyses.
We compared five groups with the group that had no previous infection and no vaccination. The five groups were characterized by type of exposure: previous infection and no vaccination, two-dose vaccination and no previous infection, two-dose vaccination and previous infection, three-dose vaccination and no previous infection, and three-dose vaccination and previous infection. The groups were defined on the basis of the status of previous immunologic events (previous infection or vaccination) at the time of the PCR test.
Classification of severe,8 critical,8 and fatal9 Covid-19 cases followed World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews as part of a national protocol applied to hospitalized patients with Covid-19. Details regarding Covid-19 severity, criticality, and fatality classification are provided in Section S1 in theSupplementary Appendix .
To estimate the effectiveness against symptomatic infection, we exactly matched cases and controls that were identified from December 23, 2021, through February 21, 2022. Case participants and controls were matched in a 1:1 ratio according to sex, 10-year age group, nationality, and calendar week of PCR test. Matching was performed to control for known differences in the risk of SARS-CoV-2 exposure in Qatar.10 (link),19 (link),20 (link) Matching according to these factors was previously shown to provide adequate control of differences in the risk of SARS-CoV-2 exposure in studies of different designs, all of which involved control groups, such as test-negative, case–control studies.11 (link),12 (link),15 (link),21 (link),22 (link) To assess effectiveness against any severe, critical, or fatal case of Covid-19, we used a 1:5 matching ratio to improve the statistical precision of the estimates.
Only the first PCR-positive test that was identified for an individual participant during the study period was included, but all PCR-negative tests were included. Controls included persons with no record of a PCR-positive test during the study period. Only PCR tests conducted because of clinical symptoms were used in the analyses.
SARS-CoV-2 reinfection is conventionally defined as a documented infection that occurs at least 90 days after an earlier infection, to avoid misclassification of prolonged PCR positivity as reinfection if a shorter time interval is used.2 (link),23 (link) Previous infection was therefore defined as a PCR-positive test that occurred at least 90 days before the PCR test used in the study. Tests for persons who had PCR-positive tests that occurred within 90 days before the PCR test used in the study were excluded. Accordingly, previous infections in this study were considered to be due to variants other than omicron, since they occurred before the omicron wave in Qatar.2-4 (link)PCR tests for persons who received vaccines other than BNT162b2 or mRNA-1273 and tests for persons who received mixed vaccines were excluded from the analyses. Tests that occurred within 14 days after a second dose or 7 days after a third dose of vaccine were excluded. These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4 (link),14 (link) and to minimize different types of potential bias, as informed by earlier analyses in the same population.12 (link),22 (link) Every control that met the inclusion criteria and that could be matched to a case was included in the analyses.
We compared five groups with the group that had no previous infection and no vaccination. The five groups were characterized by type of exposure: previous infection and no vaccination, two-dose vaccination and no previous infection, two-dose vaccination and previous infection, three-dose vaccination and no previous infection, and three-dose vaccination and previous infection. The groups were defined on the basis of the status of previous immunologic events (previous infection or vaccination) at the time of the PCR test.
Classification of severe,8 critical,8 and fatal9 Covid-19 cases followed World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews as part of a national protocol applied to hospitalized patients with Covid-19. Details regarding Covid-19 severity, criticality, and fatality classification are provided in Section S1 in the
3' Untranslated Regions
5' Untranslated Regions
Asian Americans
Buffers
Cholesterol
Citrates
Dialysis
DNA-Directed DNA Polymerase
DNA-Directed RNA Polymerase
Endotoxins
Ethanol
Genes
Homo sapiens
Lipids
Molar
Poly(A) Tail
Protein Biosynthesis
RNA, Messenger
RNA, Small Interfering
RNA Caps
S-Adenosylmethionine
Signal Peptides
Strains
Tissue Donors
TRAF3 protein, human
Transcription, Genetic
Zika Virus
Most recents protocols related to «MRNA Vaccines»
We synthesized mRNA vaccines encoding for the codon-optimized SARS-CoV-2 spike protein from USA-WA1/2020, OC43 spike protein, OVA from the SERPINB14 gene, HIV-1 SF162 envelope protein, or the LCMV GP. Constructs were purchased from Integrated DNA Technologies (IDT) or Genscript, and contained a T7 promoter site for in vitro transcription of mRNA. The sequences of the 5′- and −3′′-UTRs were identical to those used in a previous publication.44 All mRNAs were encapsulated into lipid nanoparticles using the NanoAssemblr Benchtop system (Precision NanoSystems) and confirmed to have similar encapsulation efficiency (~95%). mRNA was diluted in Formulation Buffer (Catalog # NWW0043, Precision NanoSystems) to 0.17 mg/mL and then run through a laminar flow cartridge with GenVoy ILM encapsulation lipids (Catalog # NWW0041, Precision NanoSystems) with N/P (Lipid mix/mRNA ratio of 4) at a flow ratio of 3:1 (RNA: GenVoy-ILM), with a total flow rate of 12 mL/min, to produce mRNA–lipid nanoparticles (mRNA-LNPs). mRNA-LNPs were evaluated for encapsulation efficiency and mRNA concentration using RiboGreen assay using the Quant-iT RiboGreen RNA Assay Kit (Catalog # R11490, Invitrogen, Thermo Fisher Scientific).
Full text: Click here
Our team previously reported the synthesis steps for MIC1 lipids [15 ]. LNPs for mRNA vaccines, encapsulating mRNA encoding LUC and mRNA encoding RBD linked with various signal sequences, were prepared using a microfluidic device (Micro&Nano Biologics). Initially, MIC1, DSPC, cholesterol, and DMG-PEG2k were dissolved in ethanol at a molar ratio of 35:16:46.5:2.5, forming the organic phase [49 (link)–51 (link)]. Concurrently, mRNA was dissolved in citric acid buffer (pH 6.0) to form the aqueous phase. The mRNA vaccines were then produced by mixing these organic and aqueous phases. Subsequently, ethanol was removed through ultrafiltration.
The particle size and zeta potential of the mRNA LNPs were determined using a Zetasizer Nano ZS90 (Malvern). Encapsulation efficiency was calculated as [(1 - mfree/mtotal) × 100%], following our previously established methodology [52 ]. The morphology of the mRNA vaccines was visualized using 2% phosphotungstic acid staining, observed under a TEM FEI Talos F200XG2 AEMC (Thermo Fisher).
The particle size and zeta potential of the mRNA LNPs were determined using a Zetasizer Nano ZS90 (Malvern). Encapsulation efficiency was calculated as [(1 - mfree/mtotal) × 100%], following our previously established methodology [52 ]. The morphology of the mRNA vaccines was visualized using 2% phosphotungstic acid staining, observed under a TEM FEI Talos F200XG2 AEMC (Thermo Fisher).
Full text: Click here
Kluc or GL261 GBM tumor-bearing mice were treated starting on day 6 after the intracranial injection. The cohort of mice used in this experiment were mice that received no treatment (Untreated), mice which received control unloaded DCs in combination with anti-PD-1 Ab (Ctl-DCs + PD-1) or IgG Ab (Ctl-DCs + IgG), and mice which received TOFU mRNA-pulsed DCs in combination with anti-PD-1 Ab (TOFU-DCs + PD-1) or IgG Ab (TOFU-DCs + IgG) (n = 7 mice per group). Briefly, 5 × 105 TOFU-DCs or Ctl DCs were injected intradermally along with anti-PD-1 or IgG Abs (10 mg/kg) (BioXcell, clones RMP1-14 and 2A3, respectively) delivered intraperitoneally. The DC vaccines were administered weekly for 3 weeks for a total of 3 vaccines. The anti-PD-1 and IgG Abs were administered to the mice every 3rd day for 2 weeks for a total of 5 doses. Bioluminescent imaging of the Kluc tumors was performed using luciferin substrate (Perkin Elmer LAS Inc) and the IVIS Spectrum Imaging System at the end of the treatment regimen on day 20 post the tumor implantation (n = 5 mice per group). For RNA-seq analysis of the tumor microenvironment, the animals were euthanized on day 21 after the tumor implantation (n = 4–5 mice per group) and the tumor tissue was processed for downstream analysis (see the “Tumor dissociation ” section of the methods).
Full text: Click here
The survey was initially developed to probe student ideas and attitudes about the COVID-19 vaccines. To confirm that the questions were unambiguous and elicited relevant responses (validation evidence based on response processes), we conducted think-aloud interviews with people with PhDs in biology (n = 3 people) and students taking upper-division (n = 6), lower-division (n = 5), and non-major (n = 8) biology courses (11 (link)). Because these interviews are only intended to provide feedback on the questions themselves, it is typically sufficient to interview a handful of people (12 (link)). Based on 14 initial interviews, we revised the question about the role of mRNA in the mRNA COVID vaccine to its current form. Later interviews with people from all four categories (n = 8) confirmed that the rephrased question was clear and produced responses related to the interviewee’s ideas about mRNA, central dogma, COVID vaccines, and immunity. No other questions were altered. The full text of the finalized survey is included in Appendix 1.
To induce an experimental tuberculosis infection, a model of intravenous infection of animals was employed; a dose of 500,000 CFUs per mouse was injected 3 weeks after the second vaccination. On day 50 after the infection initiation, the number of mycobacterial cells in the lungs of the infected mice was determined. To this end, the lungs were isolated in a sterile fashion and homogenized in 2 mL of saline, and serial 10-fold dilutions of the lung homogenates were prepared and plated on Petri dishes with Middlebrook 7H10 agar at 50 μL per plate. The Petri dishes were next incubated at 37 °C; after 21 days, macrocolonies of M. tuberculosis H37Rv on each plate were counted, and their number per lung was calculated.
Full text: Click here
Top products related to «MRNA Vaccines»
Sourced in United States, United Kingdom, Germany, China
BNT162b2 is a vaccine candidate developed by Pfizer and BioNTech. It is a messenger RNA (mRNA) vaccine that encodes the SARS-CoV-2 spike protein. The core function of BNT162b2 is to induce an immune response against the SARS-CoV-2 virus.
Sourced in United States, United Kingdom
MRNA-1273 is an mRNA-based vaccine candidate developed by Moderna. It is designed to encode the prefusion stabilized full-length spike protein of SARS-CoV-2. The core function of MRNA-1273 is to generate an immune response against the SARS-CoV-2 virus.
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
Sourced in United States, Germany
Comirnaty is a nucleoside-modified messenger RNA (modRNA) vaccine used for the prevention of COVID-19 disease caused by SARS-CoV-2 virus. The vaccine consists of a lipid nanoparticle formulation that encapsulates a single-stranded, 5'-capped messenger RNA (mRNA) that encodes the viral spike (S) protein of SARS-CoV-2.
Sourced in United States, Germany
Spikevax is a COVID-19 vaccine developed by Moderna. It is a mRNA-based vaccine that encodes the SARS-CoV-2 spike protein.
Sourced in Belgium, United States
Ad26.COV2.S is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a stabilized form of the SARS-CoV-2 spike (S) protein. The product is designed for laboratory use.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, United Kingdom
Expi293F cells are a suspension-adapted mammalian cell line derived from HEK293F cells. They are designed for high-level recombinant protein expression in biopharmaceutical and biotechnology applications.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
More about "MRNA Vaccines"
Discover the revolutionary world of mRNA vaccines, a transformative technology reshaping the future of vaccinology.
These novel immunizations, also known as messenger ribonucleic acid (mRNA) vaccines, harness the power of genetic instructions to stimulate the body's cells to produce specific proteins, triggering a robust immune response.
Leveraging the insights from cutting-edge mRNA vaccine research, including landmark studies on BNT162b2, MRNA-1273, Comirnaty, and Spikevax, we explore the remarkable advantages of this emerging field. mRNA vaccines offer unparalleled speed and flexibility in development, with the potential for rapid manufacturing and improved stability, addressing the urgent need for agile and accessible immunizations, as witnessed during the COVID-19 pandemic.
Beyond their role in combating infectious diseases, mRNA vaccines hold promise in tackling a wide range of health challenges, from cancer to genetic disorders.
Innovative platforms like Prism 8 and Prism 9 are at the forefront of this revolutionary approach, utilizing advanced techniques such as Expi293F cell lines and Penicillin/streptomycin to enhance potency, safety, and scalability.
Dive into the world of mRNA vaccines and discover how AI-driven analysis, leveraged by tools like PubCompare.ai, can accelerate research, optimize protocols, and identify the most effective methods.
Unlock the transformative potential of this cutting-edge technology and usher in a new era of personalized, targeted, and rapidly deployable immunizations that safeguard global health and well-being.
These novel immunizations, also known as messenger ribonucleic acid (mRNA) vaccines, harness the power of genetic instructions to stimulate the body's cells to produce specific proteins, triggering a robust immune response.
Leveraging the insights from cutting-edge mRNA vaccine research, including landmark studies on BNT162b2, MRNA-1273, Comirnaty, and Spikevax, we explore the remarkable advantages of this emerging field. mRNA vaccines offer unparalleled speed and flexibility in development, with the potential for rapid manufacturing and improved stability, addressing the urgent need for agile and accessible immunizations, as witnessed during the COVID-19 pandemic.
Beyond their role in combating infectious diseases, mRNA vaccines hold promise in tackling a wide range of health challenges, from cancer to genetic disorders.
Innovative platforms like Prism 8 and Prism 9 are at the forefront of this revolutionary approach, utilizing advanced techniques such as Expi293F cell lines and Penicillin/streptomycin to enhance potency, safety, and scalability.
Dive into the world of mRNA vaccines and discover how AI-driven analysis, leveraged by tools like PubCompare.ai, can accelerate research, optimize protocols, and identify the most effective methods.
Unlock the transformative potential of this cutting-edge technology and usher in a new era of personalized, targeted, and rapidly deployable immunizations that safeguard global health and well-being.